PTC is a novel rearranged form of the ret proto-oncogene
and is frequently detected in vivo in human thyroid papillary carcinomas.
A positive RET proto-oncogene
in codon 918 was confirmatory.
Mutations of the RET proto-oncogene causative for MEN 2 were identified in 1993.
The discovery of molecular abnormalities of the RET proto-oncogene in MEN 2 and FMTC has significantly improved clinical management of these disorders.
Key Words: medullary carcinoma, multiple endocrine neoplasia, RET proto-oncogene, pediatric neoplasm, point mutation, thyroid neoplasms
Analysis of RET proto-oncogene mutation at codon 918 should be performed in all children born to parents with MEN 2B, as well as in children with ambiguous clinical features suggestive of MEN 2B.
Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene
Cloning and expression of the ret proto-oncogene
encoding a tyrosine kinase with two potential transmembrane domains.
The RET proto-oncogene
in multiple endocrine neoplasia type 2 and Hirschsprung's disease.
The relationship between specific RET proto-oncogene
mutations and disease phenotype in multiple endocrine neoplasia type
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene
in Hirschsprung's disease.
Characterization of RET proto-oncogene
3' splicing variants and polyadenylation sites: a novel C-terminus for RET.
in the development of human cancer [Review].
Specific mutations of the RET proto-oncogene
are related to disease phenotype in MEN 2A and FMTC.
Human RET proto-oncogene
mapped to chromosome 10811.